LifeVantage Corporation (LFVN) Stock Price & Analysis
LifeVantage Corporation (LFVN) — MoonshotScore 61/100 (Fair band), calculated Nov 18, 2026. Price $4.15 (-15.13%), as of the Nov 20, 2026 trading session; market cap $52.6M.
Educational signal · not a buy or sell recommendation · How to read this
LifeVantage Corporation · LFVN · NASDAQ
LifeVantage Corporation develops and distributes nutrigenomic activators, dietary supplements, and skincare products through a network of independent distributors and its website. The company operates in multiple international markets, including the United States, Mexico, Japan, and several European countries.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · LifeVantage (LFVN)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, at a dirt-cheap price, but stalling growth. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $48M (Q1 FY2026, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 2.38 · Piotroski F 4
Holding back: soft growth, weak price trend
Helping: business quality, an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 60 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.15 | |
| Change on the day | -15.13% | |
| Market capitalisation | $52.6M | — |
| Price / earnings (trailing) | 22.31 | |
| Shares traded on the day | 72.9K |
Price & events
Other perspectives
Council score for LifeVantage (LFVN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is LifeVantage (LFVN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LifeVantage Corporation (LFVN) is listed on NASDAQ. It employs 209 people. In Q1 FY2026 it reported revenue of $48M and net income of $2M. The market values it at $52.6M.
What do the latest results show for LifeVantage (LFVN)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $48M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $48M | $2M | $0.17 (diluted) |
| Q2 FY2026 | $49M | $276,000 | $0.02 (diluted) |
| Q3 FY2026 | $44M | $1M | $0.11 (diluted) |
| Q4 FY2026 | $42M | $1M | $0.10 (diluted) |
What are the financial strengths and risks for LifeVantage (LFVN)?
Short answer · as of
The MoonshotScore pillars rate business quality, an attractive price as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 2.38 · Piotroski F 4. Trailing ratios: ROE 8.2% · ROA 4.4% · current ratio 1.91.
What should you watch next at LifeVantage (LFVN)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q1 FY2026) was filed Nov 4, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does LifeVantage compare with its peers?
Short answer
LifeVantage's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $15.53 Nov 20, 2026 | $1.63B | 92 5-pillar Nov 18, 2026 | |
| $4.93 Nov 20, 2026 | $28.1M | 85 5-pillar Nov 18, 2026 | |
| $12.94 Nov 20, 2026 | $239M | 73 5-pillar Nov 18, 2026 | |
| $6.20 Nov 20, 2026 | $58.2M | 63 5-pillar Nov 18, 2026 | |
| LifeVantage (LFVN) — this page | $4.15 | $52.6M | 61 |
| $10.18 Nov 20, 2026 | $176M | 43 5-pillar Nov 18, 2026 | |
| $5.01 Nov 20, 2026 | $45.5M | 40 5-pillar Nov 18, 2026 | |
| $19.17 Nov 20, 2026 | $290M | 39 5-pillar Nov 18, 2026 | |
| $3.80 Nov 20, 2026 | $185M | 35 5-pillar Nov 18, 2026 | |
| $1.19 Nov 20, 2026 | $28.8M | 34 5-pillar Nov 18, 2026 | |
| $7.21 Nov 20, 2026 | $181M | 34 5-pillar Nov 18, 2026 | |
| $2.15 Nov 20, 2026 | $24.2M | 33 5-pillar Nov 18, 2026 | |
| $2.37 Nov 20, 2026 | $47.6M | 28 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $6.00 – $8.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $7.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $7.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 25
- Identified insiders
- 9
- Purchases
- 2
- Sales
- 3
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LFVN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LFVN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about LifeVantage (LFVN)?
- Freedom Broker Maintains Buy on Lifevantage, Lowers Price Target to $8
- LifeVantage Corporation Reports Financial Results for First Quarter Fiscal 2027
- LifeVantage Corporation Declares Quarterly Cash Dividend
- Lifevantage Corp (LFVN) (Q1 2027) Earnings Call Highlights: Revenue Slides 22% as Strategic ...
Investor Questions: LFVN Stock
These answers are editorial: 1 of these 9 answers is drawn from the LFVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LFVN?
LFVN carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is LFVN a good stock to buy?
Stock Expert AI does not rate LFVN buy, sell or hold. LifeVantage Corporation carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LFVN stock price today?
The last price recorded for LifeVantage Corporation (LFVN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LFVN price target?
The last analyst consensus price target we captured for LifeVantage Corporation (LFVN), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What do analysts say about LFVN stock?
Analyst coverage of LifeVantage Corporation (LFVN) is limited, reflecting its small-cap status. Key valuation metrics to consider include its P/E ratio, gross margin, and dividend yield.
What are the key factors to evaluate for LFVN?
LifeVantage Corporation (LFVN) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Focusing on specific health concerns, such as cognitive function, immune support, and healthy aging, can attract new customer segments. Not financial advice.
How frequently does LFVN data refresh on this page?
LFVN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LFVN's recent stock price performance?
LifeVantage Corporation (LFVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary nutrigenomic technology and patented formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LFVN overvalued or undervalued right now?
The trailing P/E of LifeVantage Corporation (LFVN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 15 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com